Figure 6
From: Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation
Efficacy of Y9 tested in a GPC-16 tumor model in guinea pigs (A) Measurement of tumor size in GPC-16 inoculated, CPA-treated guinea pigs over 35 days. Animals receiving 1.6–2 × 107 GPC-16 cells mixed with 200 nmol of Y9 and Matrigel before injection are compared with animals receiving GPC-16 cells premixed only with PBS and Matrigel as a control. With Y9 treatment only 3 out of 10 guinea pigs carried verifiable tumors whereas in the untreated control group 8 out of 9 animals carried tumors (statistics are based on t-test for the upper graph and on a Wilcoxon-test for the engraftment comparison). (B) Tumor growth at day 35 after inoculation in guinea pig skin (HE-sections) treated with PBS control (top) or Y9 (bottom); 50x magnification.
